IMPEDIMED LIMITED — Director's Dealing 2022

Oct 30, 2022

==> picture [230 x 54] intentionally omitted <==

31 October 2022

ASX ANNOUNCEMENT

Change of Director’s Interest Notice - Correction

ImpediMed Limited (ASX.IPD) ( Impedimed , Company ) refers to an earlier lodgement today of a Change of Director’s Interest Notice for Mr Donald Williams. This notice inadvertently reported the opening balance of shares held incorrectly. The number of shares acquired on market and the balance now held were reported correctly.

The attached revised Change of Director’s Interest Notice for Mr Williams reports the correct opening balance.

This announcement was approved for release by ImpediMed Limited’s Company Secretary.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed T: +61 407 431 432 E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: ImpediMed Limited ABN: 089 705 144

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Donald Williams
Date of last notice	06 October 2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances
giving rise to the relevant interest.
Date of change	28 October 2022
No. of securities held prior to change	Direct – Don Williams
	130,000 Ordinary shares
	Direct – Jointly Held
	3,521,311 Ordinary shares
Class	Ordinary Shares
Number acquired	Direct – Jointly Held
	1,707,825
Number disposed	Nil

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration	1,487,825 at $0.088 per share
Note: If consideration is non-cash, provide	220,000 at $0.089 per share
details and estimated valuation
No. of securities held after change	Direct – Don Williams
	130,000 Ordinary shares
	Direct – Jointly Held
	5,229,136 Ordinary shares
Nature of change	On market trade.
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed	No
above traded during a+closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the
trade to proceed during this period?
If prior written clearance was provided, on what date was
this provided?

Date of Notice: 31 October 2022

• See chapter 19 for defined terms.

Appendix 3Y Page 2